Novartis AG Gross Margin 2010-2023 | NVS

Current and historical gross margin for Novartis AG (NVS) over the last 10 years. The current gross profit margin for Novartis AG as of December 31, 2023 is %.
Novartis AG Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2023-12-31 $46.66B $34.19B 73.27%
2023-09-30 $46.02B $33.53B 72.86%
2023-06-30 $44.71B $32.46B 72.61%
2023-03-31 $43.86B $32.20B 73.42%
2022-12-31 $43.46B $31.88B 73.35%
2022-09-30 $50.20B $35.75B 71.20%
2022-06-30 $52.79B $37.27B 70.60%
2022-03-31 $53.00B $37.31B 70.41%
2021-12-31 $52.88B $37.01B 69.99%
2021-09-30 $56.14B $40.03B 71.31%
2021-06-30 $51.56B $35.63B 69.12%
2021-03-31 $49.88B $34.45B 69.05%
2020-12-31 $49.90B $34.78B 69.70%
2020-09-30 $45.83B $30.94B 67.50%
2020-06-30 $49.53B $34.61B 69.88%
2020-03-31 $49.93B $35.03B 70.17%
2019-12-31 $48.68B $34.25B 70.37%
2019-09-30 $47.86B $33.39B 69.76%
2019-06-30 $46.76B $32.60B 69.72%
2019-03-31 $46.39B $32.08B 69.15%
2018-12-31 $46.10B $31.59B 68.52%
2018-09-30 $47.37B $32.41B 68.41%
2018-06-30 $48.67B $32.85B 67.49%
2018-03-31 $49.51B $32.99B 66.63%
2017-12-31 $50.14B $32.96B 65.74%
2017-09-30 $49.58B $32.40B 65.36%
2017-06-30 $49.23B $32.01B 65.02%
2017-03-31 $49.41B $32.00B 64.76%
2016-12-31 $49.44B $31.92B 64.56%
2016-09-30 $49.63B $32.05B 64.58%
2016-06-30 $49.78B $32.18B 64.64%
2016-03-31 $50.00B $32.36B 64.72%
2015-12-31 $50.39B $32.98B 65.46%
2015-09-30 $50.94B $33.67B 66.09%
2015-06-30 $51.75B $34.45B 66.56%
2015-03-31 $52.81B $35.61B 67.44%
2014-12-31 $53.63B $36.29B 67.66%
2014-09-30 $52.60B $35.92B 68.27%
2014-06-30 $52.21B $35.82B 68.60%
2014-03-31 $51.54B $35.44B 68.76%
2013-12-31 $52.72B $36.14B 68.55%
2013-09-30 $49.87B $34.85B 69.89%
2013-06-30 $51.00B $35.54B 69.68%
2013-03-31 $52.26B $36.28B 69.41%
2012-12-31 $51.97B $36.11B 69.47%
2012-09-30 $57.49B $38.70B 67.32%
2012-06-30 $58.48B $39.48B 67.51%
2012-03-31 $59.07B $40.06B 67.82%
2011-12-31 $59.38B $40.39B 68.03%
2011-09-30 $58.84B $40.45B 68.75%
2011-06-30 $56.63B $39.37B 69.52%
2011-03-31 $53.43B $37.58B 70.33%
2010-12-31 $51.56B $37.07B 71.90%
2010-09-30 $50.24B $36.61B 72.87%
2010-06-30 $48.71B $35.64B 73.16%
2010-03-31 $47.53B $34.84B 73.30%
2009-12-31 $45.10B $32.92B 73.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $209.898B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $732.877B 105.92
Novo Nordisk (NVO) Denmark $597.021B 45.88
Johnson & Johnson (JNJ) United States $371.302B 14.75
Merck (MRK) United States $331.494B 60.31
AbbVie (ABBV) United States $290.220B 14.99
AstraZeneca (AZN) United Kingdom $238.858B 20.76
Pfizer (PFE) United States $163.878B 20.37
Sanofi (SNY) $123.495B 11.65
Innoviva (INVA) United States $0.998B 7.01